Daily brief

Every weekday morning an AI co-pilot reads the overnight tape across the book, cross-references the catalyst calendar, and writes what moved and why.

• 2026-09-10Bachem's peptide franchise led while the CDMO and injectables layer softened, with Hikma the weakest on continued generics pressure.
• 2026-09-09Corning jumped on an AI-fiber deal — not its pharma glass — while the sterile-injectables chokepoint sold off across the board.
• 2026-09-07Corning rode the AI-optical bid to the top of the basket while the bioprocessing chokepoint kept sliding on margin normalization.
• 2026-09-04Thermo Fisher firmed on a CLSA initiation as the fill-finish and bioprocessing chokepoint sat out a risk-on rally.
• 2026-09-03A quiet fill-finish tape with Novo firm on GLP-1 demand and the containment names barely moving.
• 2026-09-02A defensive domestic injectables maker led while the higher-multiple bioprocessing-and-tools names de-rated in a broad risk-off.
• 2026-09-01Repligen's bioprocessing consumables led the picks-and-shovels names higher while WuXi's China-CDMO overhang kept the reshoring chokepoint under pressure.
• 2026-08-31The bioprocessing and CDMO picks-and-shovels sold off broadly in a risk-off session, with the mRNA-input chokepoint worst-hit as Maravai extended its slide and only Fujifilm's ADR firmed.
• 2026-08-28The pharma supply-chain basket lagged the AI-led tape, with only the bioprocessing name firm and Maravai's nucleic-acid line the day's clear decliner.
• 2026-08-27Corning's glass line rose on AI-optics demand while Eli Lilly fell 4% on profit-taking and a rebate-flattered quarter.
• 2026-08-26Maravai extended its post-earnings run with a 6.8% gain in the oligonucleotide-reagent choke, while a quiet pharma tape left West Pharma the only notable decliner.
• 2026-08-25The pharma supply chain held up far better than the high-beta tape, with Agilent off 3.5% into its earnings and the fill-finish and CDMO names mostly steady.
• 2026-08-24Pharma was the quiet corner of a risk-on tape, with Maravai extending its post-earnings run up 4.2% while the peptide-CDMO name Bachem eased on light volume.
• 2026-08-21Maravai jumped 14.8% extending its post-earnings run as the oligonucleotide-manufacturing choke firmed and bioprocessing tools bounced, while Eli Lilly led the demand-side names lower.
• 2026-08-20The bioprocessing-tools choke ripped — Danaher up 6.0% and Repligen 6.1% on a $1.5B deal — and small-cap Maravai rode the wave 25.8%, while Corning's glass line bucked the rally.
• 2026-08-19Pharma was a haven as tech sold — Eli Lilly's GLP-1 engine rose 3.6% — while Corning fell 7.7%, dragged not by vials but by its AI-optics business in the semiconductor rout.
• 2026-08-17A generics-and-injectables bid lifted Amneal 5% while GLP-1 pricing pressure made Eli Lilly the laggard and dragged the bioprocessing-tools choke lower.
• 2026-08-14A quiet pharma-supply tape whose biggest move, Corning down 5%, was an AI-optical and consumer-glass story wearing a pharma-glass badge, while ICU Medical drifted higher on last week's blowout.
• 2026-08-13A quiet pharma tape where the biggest mover, Corning up 5%, was an AI-optical story wearing a pharma-glass badge, while the sterile-injectables names eased.
• 2026-08-12Renewed U.S. generic-drug tariff threats hit the generics-and-bioprocess names — Amneal down 4%, Maravai down 4% — while the fill-finish chokepoint held and beaten-down Dr. Reddy's bounced.
• 2026-08-11An analyst target hike sent Eli Lilly up 4% at the fill-finish choke, while Corning fell 5% on its optical-fiber side — an AI-optics selloff, not a pharma-glass story.
• 2026-08-10ICU Medical's Q2 beat and guidance raise sent the infusion-delivery choke up 11% and the bioprocessing names caught a risk-on bid, while FUJIFILM's ADR fell on a group profit miss driven squarely by its bio-CDMO arm.
• 2026-08-07FUJIFILM's bio-CDMO cost ramp cracked its ADR 9% and put the biologics contract-manufacturing chokepoint in the spotlight, while Novo Nordisk bounced off an earnings-week slide.
• 2026-08-06Charles River jumped 11% on a beat-and-raise that declared biotech demand back, lifting the CRO-and-bioprocessing services choke, while Baxter gave back its late-July earnings pop.
• 2026-08-05Corning led the pharma-supply basket on an optical-fiber upgrade rather than glass, while Novo Nordisk's oral-Wegovy stumble made it the session's laggard.
• 2026-08-04WuXi AppTec's H1 beat and guidance raise put the CRDMO outsourcing chokepoint back in the lead, while Eli Lilly slipped as money rotated out of defensive pharma on a risk-on day.
• 2026-08-03Novo Nordisk fell 9% on a failed heart-drug trial, but the fill-finish and peptide-supply chokepoints held — Bachem even led — because the setback was a pipeline story, not an obesity-demand one.
• 2026-07-31The pharma-supply complex largely sat out the AI melt-up — Corning rebounded on optics, Baxter beat and raised, but Eli Lilly's GLP-1 softness dragged the demand anchor as 100% pharma tariffs loom.
• 2026-07-30As the market sold off on a hawkish Fed hold, the pharma supply chain was the day's defensive haven — domestic injectables, CDMO capacity and containment names caught a genuine rotation bid days before Section 232 tariffs land.
• 2026-07-29Bioprocessing beat, packaging broke — Repligen surged on a raised guide while Corning's post-earnings plunge dragged the pharma-glass chokepoint, with 100% pharma tariffs now days away.